CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: SLC26A2 (ImmuneEditome ID:1836)

1. Gene summary of enriched editing regions for SLC26A2

check button Gene summary
Gene informationGene symbol

SLC26A2

Gene ID

1836

GeneSynonymsD5S1708|DTD|DTDST|EDM4|MST153|MSTP157
GeneCytomap

5q32

GeneTypeprotein-coding
GeneDescriptionsulfate transporter|diastrophic dysplasia protein|solute carrier family 26 (anion exchanger), member 2|solute carrier family 26 (sulfate transporter), member 2|sulfate anion transporter 1
GeneModificationdate20230329
UniprotIDP50443;H0YA38;C9JAN6
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr5:149983602-149984631:+ENST00000286298.4ENSG00000155850.7SLC26A2UTR3AluSc8,AluJrchr5:149983602-149984631:+.alignment


Top

2. Tumor-specific enriched editing regions for SLC26A2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr5:149983602-149984631:+BRCAEER2.2020e-35image
ENSG00000155850.7,SLC26A2BRCAEAG1.2288e-33image
chr5:149983602-149984631:+COADEER4.0358e-02image
chr5:149983602-149984631:+HNSCEER4.2168e-11image
ENSG00000155850.7,SLC26A2HNSCEAG1.6922e-10image
chr5:149983602-149984631:+KIRCEER4.7544e-05image
ENSG00000155850.7,SLC26A2KIRCEAG6.5667e-05image
chr5:149983602-149984631:+LUADEER2.8755e-04image
ENSG00000155850.7,SLC26A2LUADEAG1.0858e-04image
chr5:149983602-149984631:+LUSCEER6.2773e-04image
ENSG00000155850.7,SLC26A2LUSCEAG2.8434e-05image
ENSG00000155850.7,SLC26A2PRADEAG3.8090e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr5:149983602-149984631:+KIRPEER3.8431e-024.1693e-022.6592e+03image

Top

3. Enriched editing regions and immune related genes for SLC26A2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr5:149983602-149984631:+GBMEERENSG00000121931,LRIF10.29702.3832e-026.9150e-070.4253imageNNNAMacrophages_M1GSVA_HALLMARK_MYOGENESIS
chr5:149983602-149984631:+GBMEERENSG00000185798,WDR530.29972.4473e-025.0387e-070.4300imageNNNAGSVA_HALLMARK_HEDGEHOG_SIGNALING
chr5:149983602-149984631:+GBMEERENSG00000129055,ANAPC130.27754.1919e-022.3661e-060.4062imageNNNAGSVA_HALLMARK_APICAL_JUNCTION
chr5:149983602-149984631:+STADEERENSG00000238000,RP11-274E7.20.38051.1152e-075.0849e-120.4005imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr5:149983602-149984631:+ESCAEERENSG00000266563,EIF1P50.31801.5918e-024.5289e-080.4351imageNNNAPlasma_cellsGSVA_HALLMARK_KRAS_SIGNALING_DN

More results



Top

4. Enriched editing regions and immune related splicing for SLC26A2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr5:149983602-149984631:+
ESCAEERA5ENSG00000173801.12chr1741771818:41771859:41772817:41772926:41772546:41772926-0.21192.8647e-022.1261e-06-0.4437imageNNJUPMast_cells_restingGSVA_HALLMARK_INFLAMMATORY_RESPONSE
ENSG00000155850.7,SLC26A2
ESCAEAGA5ENSG00000173801.12chr1741771818:41771859:41772817:41772926:41772546:41772926-0.20693.3842e-024.4835e-06-0.4199imageNACIN1;ADAR;AUH;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NOP56;NOP58;NUMA1;PCBP2;PTBP1;QKI;RANGAP1;RBFOX2;RNF219;SAFB2;SND1;SRSF1;SRSF10;TAF15;TARDBP;TIA1;TIAL1;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZNF184JUPMast_cells_restingGSVA_HALLMARK_INFLAMMATORY_RESPONSE
chr5:149983602-149984631:+
STADEERIRENSG00000111237.14chr12110498819:110498859:110499534:110499546-0.38384.5734e-087.0153e-12-0.4008imageNNNAT_cells_CD4_naiveGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results



Top

5. Enriched editing regions and immune infiltration for SLC26A2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr5:149983602-149984631:+BLCAEERT_cells_CD4_naive4.6535e-02-0.1482image
ENSG00000155850.7,SLC26A2BLCAEAGT_cells_CD4_naive4.5654e-02-0.1479image
chr5:149983602-149984631:+BRCAEERB_cells_naive3.0091e-06-0.1539image
ENSG00000155850.7,SLC26A2BRCAEAGB_cells_naive1.2418e-06-0.1595image
chr5:149983602-149984631:+CESCEEREosinophils1.0513e-02-0.2063image
ENSG00000155850.7,SLC26A2CESCEAGEosinophils1.2040e-02-0.2026image
chr5:149983602-149984631:+CHOLEERT_cells_CD4_memory_activated5.3281e-03-0.5983image
ENSG00000155850.7,SLC26A2CHOLEAGT_cells_CD4_memory_activated7.1694e-03-0.5814image
chr5:149983602-149984631:+COADEERPlasma_cells7.7236e-03-0.1812image
ENSG00000155850.7,SLC26A2COADEAGPlasma_cells6.1728e-03-0.1862image
chr5:149983602-149984631:+ESCAEERDendritic_cells_resting7.5981e-03-0.2208image
ENSG00000155850.7,SLC26A2ESCAEAGDendritic_cells_resting1.6318e-02-0.1952image
chr5:149983602-149984631:+HNSCEERB_cells_naive5.6595e-03-0.1543image
ENSG00000155850.7,SLC26A2HNSCEAGB_cells_naive7.0988e-03-0.1500image
chr5:149983602-149984631:+KICHEERT_cells_gamma_delta2.2124e-020.4096image
ENSG00000155850.7,SLC26A2KICHEAGT_cells_gamma_delta3.5853e-020.3783image
chr5:149983602-149984631:+KIRCEERB_cells_memory1.3485e-020.1395image
ENSG00000155850.7,SLC26A2KIRCEAGT_cells_regulatory_(Tregs)7.9822e-030.1492image
chr5:149983602-149984631:+KIRPEERNeutrophils3.2459e-020.1996image
ENSG00000155850.7,SLC26A2KIRPEAGNeutrophils3.1269e-020.2010image
chr5:149983602-149984631:+LGGEERMacrophages_M06.9343e-05-0.2643image
ENSG00000155850.7,SLC26A2LGGEAGMacrophages_M06.7662e-05-0.2641image
chr5:149983602-149984631:+LUADEERDendritic_cells_resting5.0755e-040.1799image
ENSG00000155850.7,SLC26A2LUADEAGDendritic_cells_resting4.1313e-040.1822image
chr5:149983602-149984631:+LUSCEERT_cells_regulatory_(Tregs)5.9570e-050.2042image
ENSG00000155850.7,SLC26A2LUSCEAGT_cells_regulatory_(Tregs)8.5038e-050.1997image
chr5:149983602-149984631:+MESOEERMacrophages_M11.6307e-020.3382image
ENSG00000155850.7,SLC26A2MESOEAGMacrophages_M11.3262e-020.3480image
chr5:149983602-149984631:+OVEERMast_cells_resting1.6747e-02-0.1597image
ENSG00000155850.7,SLC26A2OVEAGMacrophages_M23.4313e-020.1415image
chr5:149983602-149984631:+PAADEERT_cells_CD4_naive3.9745e-030.2678image
ENSG00000155850.7,SLC26A2PAADEAGT_cells_CD4_naive3.8985e-030.2683image
chr5:149983602-149984631:+PCPGEERMacrophages_M11.3160e-020.2076image
ENSG00000155850.7,SLC26A2PCPGEAGMacrophages_M12.0547e-020.1942image
chr5:149983602-149984631:+PRADEERT_cells_regulatory_(Tregs)8.7538e-050.1880image
ENSG00000155850.7,SLC26A2PRADEAGT_cells_regulatory_(Tregs)2.2587e-040.1770image
chr5:149983602-149984631:+READEERDendritic_cells_activated1.1150e-02-0.2709image
ENSG00000155850.7,SLC26A2READEAGDendritic_cells_activated1.6791e-02-0.2558image
chr5:149983602-149984631:+SARCEEREosinophils2.2621e-020.1802image
ENSG00000155850.7,SLC26A2SARCEAGEosinophils2.0361e-020.1833image
chr5:149983602-149984631:+SKCMEERT_cells_follicular_helper8.3075e-030.1291image
ENSG00000155850.7,SLC26A2SKCMEAGT_cells_follicular_helper7.4090e-030.1310image
chr5:149983602-149984631:+STADEERMast_cells_resting4.0347e-03-0.1729image
ENSG00000155850.7,SLC26A2STADEAGT_cells_CD82.8996e-030.1752image
chr5:149983602-149984631:+TGCTEERMacrophages_M21.1851e-04-0.4499image
ENSG00000155850.7,SLC26A2TGCTEAGMacrophages_M21.9044e-04-0.4376image
chr5:149983602-149984631:+THCAEERNK_cells_resting2.5575e-020.1165image
ENSG00000155850.7,SLC26A2THCAEAGNK_cells_resting2.2416e-020.1192image
chr5:149983602-149984631:+THYMEERMacrophages_M03.2429e-02-0.3389image
ENSG00000155850.7,SLC26A2THYMEAGT_cells_follicular_helper2.8580e-020.3421image
chr5:149983602-149984631:+UCECEERDendritic_cells_resting1.0056e-02-0.2332image
ENSG00000155850.7,SLC26A2UCECEAGDendritic_cells_resting1.2762e-02-0.2258image
chr5:149983602-149984631:+UCSEERB_cells_naive2.2797e-02-0.4077image
ENSG00000155850.7,SLC26A2UCSEAGB_cells_naive3.6587e-02-0.3770image
chr5:149983602-149984631:+UVMEERT_cells_CD81.0364e-020.4609image
ENSG00000155850.7,SLC26A2UVMEAGT_cells_CD81.0853e-020.4584image


Top

6. Enriched editing regions and immune gene sets for SLC26A2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr5:149983602-149984631:+BRCAEER1.0300e-02image3.9392e-04-0.1171image
ENSG00000155850.7,SLC26A2BRCAEAG3.7426e-03image3.4286e-03-0.0967image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr5:149983602-149984631:+BRCAEER2.5903e-030.09968.0987e-030.08769.4018e-030.08603.2260e-02-0.0709image
chr5:149983602-149984631:+STADEER1.9580e-060.28232.9024e-020.13172.1123e-040.22171.2163e-020.1510image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000155850.7,SLC26A2ACCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.3787e-020.2802image
chr5:149983602-149984631:+ACCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.6155e-020.2758image
chr5:149983602-149984631:+BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER2.6116e-030.2225image
ENSG00000155850.7,SLC26A2BLCAGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG3.0786e-030.2177image
chr5:149983602-149984631:+BRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER6.5793e-110.2140image
ENSG00000155850.7,SLC26A2BRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG2.3709e-130.2390image
chr5:149983602-149984631:+CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.4186e-030.2290image
ENSG00000155850.7,SLC26A2CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.8111e-030.2268image
chr5:149983602-149984631:+COADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER1.3112e-02-0.1690image
ENSG00000155850.7,SLC26A2COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.3484e-020.1451image
ENSG00000155850.7,SLC26A2ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.0671e-030.2325image
chr5:149983602-149984631:+ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.8715e-030.2236image
chr5:149983602-149984631:+GBMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER7.0858e-03-0.2388image
ENSG00000155850.7,SLC26A2GBMGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG7.2745e-03-0.2380image
chr5:149983602-149984631:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.8455e-060.2485image
ENSG00000155850.7,SLC26A2HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG9.3813e-060.2445image
ENSG00000155850.7,SLC26A2KIRCGSVA_HALLMARK_UV_RESPONSE_DNEAG9.6457e-05-0.2179image
chr5:149983602-149984631:+KIRCGSVA_HALLMARK_UV_RESPONSE_DNEER6.1782e-04-0.1925image
ENSG00000155850.7,SLC26A2KIRPGSVA_HALLMARK_MYC_TARGETS_V1EAG2.7682e-020.2054image
chr5:149983602-149984631:+KIRPGSVA_HALLMARK_MYC_TARGETS_V1EER2.1740e-020.2138image
ENSG00000155850.7,SLC26A2LGGGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG9.7839e-05-0.2585image
chr5:149983602-149984631:+LGGGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER6.6272e-05-0.2650image
ENSG00000155850.7,SLC26A2LUADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG4.1573e-02-0.1057image
chr5:149983602-149984631:+LUADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER3.0068e-02-0.1128image
chr5:149983602-149984631:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.3834e-060.2390image
ENSG00000155850.7,SLC26A2LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.4808e-060.2284image
chr5:149983602-149984631:+OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.1812e-040.2338image
ENSG00000155850.7,SLC26A2OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6346e-030.2093image
chr5:149983602-149984631:+PAADGSVA_HALLMARK_GLYCOLYSISEER7.3080e-030.2500image
ENSG00000155850.7,SLC26A2PAADGSVA_HALLMARK_GLYCOLYSISEAG6.8020e-030.2522image
chr5:149983602-149984631:+PCPGGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4314e-020.2052image
ENSG00000155850.7,SLC26A2PCPGGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.8199e-020.1980image
ENSG00000155850.7,SLC26A2PRADGSVA_HALLMARK_UV_RESPONSE_DNEAG8.6493e-04-0.1601image
chr5:149983602-149984631:+PRADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.3933e-030.1461image
chr5:149983602-149984631:+READGSVA_HALLMARK_HYPOXIAEER1.9947e-030.3270image
ENSG00000155850.7,SLC26A2READGSVA_HALLMARK_HYPOXIAEAG3.4556e-030.3102image
ENSG00000155850.7,SLC26A2SARCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG3.1152e-03-0.2323image
chr5:149983602-149984631:+SARCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER2.4133e-03-0.2383image
ENSG00000155850.7,SLC26A2SKCMGSVA_HALLMARK_P53_PATHWAYEAG8.7387e-050.1909image
chr5:149983602-149984631:+SKCMGSVA_HALLMARK_P53_PATHWAYEER6.5339e-050.1942image
chr5:149983602-149984631:+STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.3236e-070.3116image
ENSG00000155850.7,SLC26A2STADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG8.5068e-080.3097image
chr5:149983602-149984631:+TGCTGSVA_HALLMARK_SPERMATOGENESISEER4.0366e-040.4170image
ENSG00000155850.7,SLC26A2TGCTGSVA_HALLMARK_SPERMATOGENESISEAG5.8264e-040.4065image
ENSG00000155850.7,SLC26A2THCAGSVA_HALLMARK_UV_RESPONSE_DNEAG2.1449e-05-0.2198image
chr5:149983602-149984631:+THCAGSVA_HALLMARK_UV_RESPONSE_DNEER4.7418e-05-0.2107image
chr5:149983602-149984631:+THYMGSVA_HALLMARK_HYPOXIAEER3.2536e-02-0.3387image
chr5:149983602-149984631:+UCECGSVA_HALLMARK_ANDROGEN_RESPONSEEER8.6707e-04-0.2989image
ENSG00000155850.7,SLC26A2UCECGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.4223e-03-0.2869image
chr5:149983602-149984631:+UCSGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER6.2916e-070.7622image
ENSG00000155850.7,SLC26A2UCSGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.6948e-060.7430image
chr5:149983602-149984631:+UVMGSVA_HALLMARK_PANCREAS_BETA_CELLSEER5.4066e-040.5939image
ENSG00000155850.7,SLC26A2UVMGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG5.4842e-040.5933image


Top

7. Enriched editing regions and drugs for SLC26A2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000155850.7,SLC26A2ACCBIRB.0796EAG4.3031e-02-0.2518image
chr5:149983602-149984631:+ACCBX.795EER3.8283e-02-0.2576image
chr5:149983602-149984631:+BLCAEHT.1864EER3.1541e-040.2648image
ENSG00000155850.7,SLC26A2BLCACGP.60474EAG2.7493e-04-0.2659image
chr5:149983602-149984631:+BRCABexaroteneEER3.6987e-060.1526image
ENSG00000155850.7,SLC26A2BRCABexaroteneEAG1.2243e-050.1440image
ENSG00000155850.7,SLC26A2CESCAZD6244EAG2.8349e-02-0.1773image
chr5:149983602-149984631:+CESCAZD6244EER2.3816e-02-0.1827image
ENSG00000155850.7,SLC26A2CHOLCI.1040EAG1.2440e-020.5476image
chr5:149983602-149984631:+CHOLCI.1040EER1.2324e-020.5482image
chr5:149983602-149984631:+COADGDC.0449EER3.3600e-020.1450image
ENSG00000155850.7,SLC26A2ESCAFH535EAG3.8009e-030.2342image
chr5:149983602-149984631:+ESCAFH535EER9.2696e-030.2154image
chr5:149983602-149984631:+GBMJNJ.26854165EER1.1743e-020.2238image
ENSG00000155850.7,SLC26A2GBMJNJ.26854165EAG1.1871e-020.2235image
ENSG00000155850.7,SLC26A2HNSCErlotinibEAG1.6636e-09-0.3283image
chr5:149983602-149984631:+HNSCErlotinibEER1.7657e-09-0.3283image
ENSG00000155850.7,SLC26A2KIRCGNF.2EAG4.5607e-05-0.2276image
chr5:149983602-149984631:+KIRCDasatinibEER4.5007e-04-0.1975image
ENSG00000155850.7,SLC26A2KIRPAZD6482EAG2.2432e-020.2128image
chr5:149983602-149984631:+KIRPAZD6244EER1.8670e-020.2190image
ENSG00000155850.7,SLC26A2LGGBX.795EAG6.4912e-040.2272image
chr5:149983602-149984631:+LGGBX.795EER7.1968e-040.2258image
ENSG00000155850.7,SLC26A2LUADAZD8055EAG2.6784e-030.1552image
chr5:149983602-149984631:+LUADAZD8055EER4.0087e-030.1493image
chr5:149983602-149984631:+LUSCGemcitabineEER3.7892e-05-0.2094image
ENSG00000155850.7,SLC26A2LUSCGemcitabineEAG3.9918e-05-0.2086image
chr5:149983602-149984631:+OVEmbelinEER3.8427e-060.3031image
ENSG00000155850.7,SLC26A2OVEmbelinEAG1.5202e-060.3148image
ENSG00000155850.7,SLC26A2PAADAZD6482EAG2.5028e-020.2136image
chr5:149983602-149984631:+PAADAZD6482EER3.5158e-020.2011image
chr5:149983602-149984631:+PCPGAZD6482EER4.2330e-020.1706image
ENSG00000155850.7,SLC26A2PRADDMOGEAG5.0922e-060.2179image
chr5:149983602-149984631:+PRADDMOGEER1.5029e-050.2071image
chr5:149983602-149984631:+READDMOGEER1.9768e-03-0.3272image
ENSG00000155850.7,SLC26A2READDMOGEAG2.3055e-03-0.3226image
ENSG00000155850.7,SLC26A2SARCKU.55933EAG1.1387e-03-0.2550image
chr5:149983602-149984631:+SARCKU.55933EER1.0792e-03-0.2561image
chr5:149983602-149984631:+SKCMABT.263EER1.7555e-020.1164image
ENSG00000155850.7,SLC26A2SKCMEmbelinEAG7.3689e-030.1310image
ENSG00000155850.7,SLC26A2STADBMS.509744EAG5.0916e-05-0.2368image
chr5:149983602-149984631:+STADCCT007093EER2.9859e-050.2489image
chr5:149983602-149984631:+TGCTAxitinibEER3.1637e-03-0.3529image
ENSG00000155850.7,SLC26A2TGCTAxitinibEAG4.4050e-03-0.3412image
ENSG00000155850.7,SLC26A2THCAEmbelinEAG2.7756e-050.2169image
chr5:149983602-149984631:+THCAEmbelinEER3.7352e-050.2135image
chr5:149983602-149984631:+THYMA.770041EER1.1311e-020.3965image
ENSG00000155850.7,SLC26A2THYMA.770041EAG7.7439e-030.4101image
ENSG00000155850.7,SLC26A2UCECAKT.inhibitor.VIIIEAG1.2451e-020.2266image
ENSG00000155850.7,SLC26A2UCSMG.132EAG2.9212e-05-0.6767image
chr5:149983602-149984631:+UCSMG.132EER8.4103e-05-0.6469image
ENSG00000155850.7,SLC26A2UVMFTI.277EAG3.7803e-030.5125image
chr5:149983602-149984631:+UVMFTI.277EER3.7727e-030.5127image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType